Please assess the completion status of the following clinical trial:

Trial Title: A Trial in Subjects Suspected to Have Tuberculosis, Comparing the Diagnostic Performance of C-Tb to QuantiFERON®, in Combination With a Safety Assessment of C-Tb Versus Tuberculin PPD RT23 SSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~HIV NEGATIVE PARTICIPANTS:~1. Participants between 5 and 65 years attending the TB clinic due to suspicion of TB disease~2. Infants, toddlers and children between 28 days and 4 years must either have symptoms or signs of TB or be in close contact to a smear positive pulmonary TB case (more than 6 hours/day for at least five days)~3. Is between 28 days and 65 years of age~4. Participant, parent or legal guardian has signed the informed consent~5. Is HIV negative confirmed by two rapid tests. However, children between 28 days and 4 years may have an unknown HIV status and may receive antiretroviral therapy (ART) or have breastfeeding mothers on ART~6. Is willing and likely to comply with the trial procedures~7. Is prepared to grant authorized persons access to their medical record~HIV POSITIVE PARTICIPANTS:~1. Participants between 5 and 65 years attending the TB clinic due to suspicion of TB disease~2. Infants, toddlers and children between 28 days and 4 years must either have symptoms\* or signs\*\* of TB or be in close contact to a smear positive pulmonary TB case (more than 6 hours/day for at least five days)~3. Is between 28 days and 65 years of age~4. Participant, parent or legal guardian has signed the informed consent~5. Is HIV positive confirmed by:~   1. two positive rapid tests or~  2. 1 positive rapid test and an additional confirmatory ELISA test~6. A CD4 count has been done~7. Is willing and likely to comply with the trial procedures~8. Is prepared to grant authorized persons access to their medical record~HIV NEGATIVE CONTROL GROUP:~1. Participant with no known contact to people infected with MTb and no signs or symptoms of TB.~2. Is between 5 and 11 years of age~3. Participant, parent or legal guardian has signed the informed consent~4. Is HIV negative confirmed by two rapid tests~5. Is willing and likely to comply with the trial procedures~6. Is prepared to grant authorized persons access to their medical record~Exclusion Criteria:~HIV NEGATIVE PARTICIPANTS:~1. Has a confirmed diagnosis of tuberculosis at Screening Visit~2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines) except BCG vaccine~3. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion~4. Is pregnant, breastfeeding or intending to get pregnant during the trial period~5. Is a female of child bearing potential (12 years of age or older) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures during the trial period~6. Has an active disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~7. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~8. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders or significantly impaired venous access~9. Currently participating in another clinical trial with an investigational or non-investigational drug or device or has participated in another clinical trial within the 3 months prior to dosing~10. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens~11. Has a condition which in the opinion of the investigator is not suitable for participation in the trial~HIV POSITIVE PARTICIPANTS:~1. Has a confirmed diagnosis of tuberculosis at Screening Visit~2. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines)~3. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion~4. Is pregnant, breastfeeding or intending to get pregnant during the trial period~5. Is a female of child bearing potential (12 years of age or older) not willing to use effective barrier (including spermicidal gel), hormonal or intrauterine contraceptive measures during the trial period~6. Has an active disease affecting the lymphoid organs except for HIV (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~7. Has a known diagnosis of AIDS or is receiving antiviral therapy at the time of Screening Visit~8. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~9. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders or significantly impaired venous access~10. Currently participating in another clinical trial with an investigational or non-investigational drug or device or has participated in another clinical trial within the 3 months prior to dosing~11. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens~12. Has a condition which in the opinion of the investigator is not suitable for participation in the trial~HIV NEGATIVE CONTROL GROUP:~1. Has been vaccinated with a live vaccine within 6 weeks prior to the day of inclusion (e.g. MMR, yellow fever, oral typhoid vaccines) except BCG vaccine~2. Has been tuberculin (TST) tested less than 12 months prior to the day of inclusion~3. Has an active disease affecting the lymphoid organs (e.g., Hodgkin's disease, lymphoma, leukaemia, sarcoidosis)~4. Has a current skin condition which interferes with the reading of the C-Tb and PPD e.g. tattoos, severe scarring, burns/sunburns, rash, eczema, psoriasis, or any other skin disease at or near the injection sites~5. Has a condition where blood drawings pose more than minimal risk for the participant, such as haemophilia, other coagulation disorders, or significantly impaired venous access~6. Currently participating in another clinical trial with an investigational or non-investigational drug or device, or has participated in another clinical trial within the 3 months prior to dosing~7. Has participated in previous clinical trials investigating the ESAT-6 and/or CFP-10 antigens~8. Has a condition which in the opinion of the investigator is not suitable for participation in the trial

- Gender: ALL
- Minimum Age: 28 Days
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 0.1 µg/0.1 mL C-Tb (Type: EXPERIMENTAL): The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme
- 2 T.U. Tuberculin PPD RT 23 SSI (Type: ACTIVE_COMPARATOR): The C-Tb and 2 T.U. Tuberculin PPD RT 23 SSI agents are given concomitantly to each volunteer in the RIGHT and LEFT forearms according to a double blind randomisation scheme

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete